|
Polydex Pharmaceuticals Limited |
|
|
421 Comstock Rd Toronto, Ontario M1L 2H5 Canada phone:416-755-2231 fax:416-7550334
|
|
| Symbol |
POLXF |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.polydex.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Polydex Pharmaceuticals Limited develops and manufactures dextran-based products for use in drug delivery and in therapeutic compounds. |
 |
| Management |
| MR. GEORGE USHER, Chairman, President and CEO; MR. JOSEPH BUCHMAN, Director; MR. DEREK LEDERER C.A., Director; MR. JOHN L.E. SEIDLER, Director |
| |
|
|
|
|
|
|
|
| Keywords |
| iron supplement, contraceptive, HIV, gonorrhea, herpes, HIVAIDS |
|
|
|
| Description |
|
Polydex Pharmaceuticals Limited develops and manufactures dextran-based products for use in drug delivery and in therapeutic compounds with a variety of health care applications. |
 |
| Products / Services |
Polydex Pharmaceuticals holds extensive patents covering Ushercell's synthesis and its use as a contraceptive antimicrobial agent protecting against HIV, gonorrhea, chlamydia trachomatis and herpes simplex virus 1 and 2. Currently the lead product in the Polydex pipeline, Ushercell is a high-molecular-weight cellulose sulphate compound currently in late stage human clinical trials.DextranDextran SulphateIron Dextran 10% and 20%DEAE Dextran
|
 |
 |
| Status |
| Polydex Pharmaceuticals has been in continuous operation since 1969. The Companys business continues to be based on a solid foundation: real sales, positive cash flow and tangible material assets. The sale of the veterinary subsidiary provided a cash injection into the company in 2004. The Company plans to devote sale proceeds to raising manufacturing standards and increasing capacity either by expanding the present facility or relocating to another facility to meet growing demand for core products such as Iron Dextran and additional products such as Copper Dextran. |
 |
|
|
|
|
|
|